CME Presentations

SGLT2i in CKD


Presentations


Speakers

  • Richard S. Beaser, MD

    Richard S. Beaser, MD

    Richard S. Beaser, MD

    Associate Professor of Medicine

    Richard S. Beaser, M.D., is a practicing physician in the Joslin Clinic and holds the position of Associate Clinical Professor of Medicine at Harvard Medical School. He has also been the Medical Executive Director of Professional Education at Joslin and was instrumental in developing that activity at Joslin, a department he founded in 1990. Dr. Beaser graduated in 1973 from Trinity College, Hartford, and received his medical degree from Boston University School of Medicine in 1977. He served as a resident in internal medicine at the University of Massachusetts Medical Center in Worcester from 1977-1980. He was a fellow in endocrinology at the Joslin Diabetes Center, Boston, MA 1980-81, and in Endocrinology at the Lahey Clinic Medical Center, Burlington, MA 1981-82. Dr. Beaser has been on the staff of the Joslin Diabetes Center since 1982. He has held numerous past positions at Joslin, including Section Chief of the Adult Diabetology Practice, Medical Director of the Diabetes Treatment Unit, Coordinator of the Patient Education Section, and Medical Director of Joslin TrialNet, a clinical trials network. He has been a clinical research investigator, including the landmark Diabetes Control and Complications Trial. Dr. Beaser has authored 4 books: Joslin Diabetes Manual, Outsmarting Diabetes, The Joslin Guide to Diabetes, and Joslin’s Diabetes Deskbook: A Guide for Primary Care Providers. Dr Beaser is a well-known national lecturer on clinical diabetes and its comorbidities. He is the author of numerous publications in peer review journals, review articles, and book chapters. In his role as Medical Executive Director of Professional Education at Joslin Diabetes Center, and currently as the Chair of the CME Committee, Dr. Beaser has a specific focus on development or oversight of educational content for the department, targeting physicians, other medical professionals, and patients. He leads departmental conceptualization and development of projects and activities.
  • Muthiah Vaduganathan, MD, MPH, FACC

    Muthiah Vaduganathan, MD, MPH, FACC

    Muthiah Vaduganathan, MD, MPH, FACC

    Instructor in Medicine

    Muthiah Vaduganathan, MD, MPH, is an instructor of medicine at Harvard Medical School, and is an associate physician in the Center for Advanced Heart Failure/Cardiomyopathy at Brigham and Women’s Hospital in Boston, Massachusetts. Dr. Vaduganathan’s research relates to drug development and clinical trials of cardiometabolic therapies, which has allowed him to author or co-author over 275 peer-reviewed publications. He serves on the editorial boards of the European Journal of Heart Failure and JACC Heart Failure, and on the ACCF/AHA Task Force on Performance Measures. He is a co-chair on an FDA Think Tank committee to improve future clinical trials in heart failure, and participates as a Clinical Endpoints Committee member for ongoing, advanced-phase trials in heart failure.
  • Kamyar Kalantar-Zadeh, MD, MPH, PhD

    Kamyar Kalantar-Zadeh, MD, MPH, PhD

    Kamyar Kalantar-Zadeh, MD, MPH, PhD

    Tenured Professor of Medicine, Pediatrics, Public Health and Nursing Sciences

    Kamyar Kalantar-Zadeh, MD, MPH, PhD, is chief of the Division of Nephrology, Hypertension, and Kidney Transplantation, and tenured professor of medicine, pediatrics, public health, and nursing services at University of California Irvine, School of Medicine. His core focus is nutrition and diet in the management of kidney health and disease, as well as dialysis transition and therapies. Dr Kalantar has authored more than 900 papers and has had numerous NIH grants as principal investigator. He is past president of the International Society of Renal Nutrition & Metabolism (ISRNM) and co-chair of the World Kidney Day Steering Committee. Dr Kalantar serves as editor in chief of the Journal of Renal Nutrition.

CME Information

SGLT2i in CKD: New Opportunities to Reduce the Progression of Kidney Failure


Joslin Logo PQH Logo

LEARNING OBJECTIVES

After completing this activity, the participant should be better able to:
  • Identify the limitations of current preventive strategies and treatments for CKD, along with the residual need to further reduce associated impacts on CVD and overall mortality risk
  • Summarize new evidence supporting the impact of SGLT2 inhibitors on the onset and progression of CKD, including conversion to end-stage renal disease (ESRD), in people with and without diabetes
  • Discuss currently indicated methods to use SGLT2 inhibitors to blunt the progression of CKD, as well as the potential evolution of this usage as additional supportive data are released
  • Apply the evidence-based indications and clinical support for treatment with SGLT2 inhibitors to slow the decline of renal function
  • Discuss the safety and efficacy profile of SGLT2 inhibitors when used in people with impaired renal function
  • Individualize strategies for initial dosing and treatment titration of SGLT2 inhibitors based on stages of renal function as reflected by eGFR and other key clinical parameters
Presented by Joslin Diabetes Center in Joint Providership with PlatformQ Health Education, LLC, working in collaboration with the Cardio Renal Society of America (CRSA)

ACKNOWLEDGEMENT

This activity is supported by independent educational grants from AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company.

TUITION

Complimentary

ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Joslin Diabetes Center and PlatformQ Health Education, LLC. Joslin Diabetes Center is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Live Internet Activities

Joslin Diabetes Center designates this live activity for a maximum of 1.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activities.

Enduring Material

Joslin Diabetes Center designates this enduring activity for a maximum of 1.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DATE OF RELEASE/EXPIRATION

Live Internet Activities

Thursday, June 10, 2021, from 2:00 – 3:00 PM ET: SGLT2 Inhibitors and Chronic Kidney Disease: A Broadening Clinical Perspective
Thursday, June 10, 2021, from 3:00 – 3:45 PM ET: SGLT2 Inhibitors and Their Impact on Chronic Kidney Disease: Case Workshop in Reducing Progression

Enduring Activities

The enduring material will be available from June 10, 2021 - June 10, 2022.
  • SGLT2 Inhibitors and Chronic Kidney Disease: A Broadening Clinical Perspective
  • SGLT2 Inhibitors and Their Impact on Chronic Kidney Disease: Case Workshop in Reducing Progression

INTENDED AUDIENCE

Nephrologists and primary care providers. The secondary audiences are endocrinologists, cardiologists, specialists in internal medicine (MDs and DOs), nurse practitioners, physician assistants, nurses, and pharmacists.

METHOD OF PARTICIPATION

There are no fees to participate in this activity. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the posttest and activity evaluation. It is estimated that these modules will take approximately 1 hour and 45 minutes to complete. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the posttest.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FACULTY DISCLOSURES

As part of its accreditation with the Accreditation Council for Continuing Medical Education, Joslin Diabetes Center must disclose to the audience of a Joslin continuing medical education activity the existence of any relevant financial relationships between Joslin and/or its planning and/or CME advisory committee members, speakers, and their spouses/partners and commercial entities. Joslin and its planning and CME advisory committee members and speakers must disclose any relationships they and their spouses/partners have or have had in the prior 12 months with proprietary entities producing healthcare goods or services, with the exception of nonprofit or government organizations and non-healthcare-related companies, which are exempt.

Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fees, honoraria, ownership interests (e.g., stocks, stock options, or other ownership interest, excluding diversified mutual funds), or other financial benefit in any amount. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected.

If a faculty or planning committee member has no information to disclose, this information will also be provided. If a faculty or planning committee member refuses to disclose, he/she will not be able to participate in the planning, management, presentation, or evaluation of any Joslin Diabetes Center CME activity. In addition, faculty have been asked to disclose when a product or device is not labeled for the use under discussion. The opinions and comments expressed in this program are those of the speakers and should not be considered the opinions or comments of Joslin Diabetes Center.

The planners and faculty have reported the following financial relationships with commercial interests. Via Joslin internal review, any relationship deemed relevant to the content of this activity has been identified and resolved through Joslin’s internal processes.

The faculty and planning committee members for this program have disclosed the following:

Faculty
• Dr. Richard S. Beaser*†, Senior Staff Physician and Medical Director of CME, Joslin Diabetes Center, has no relevant financial relationships with regard to this activity.
• Kamyar Kalantar-Zadeh, MD, MPH, PhD, Chief, Division of Nephrology, Hypertension and Kidney Transplantation, Tenured Professor of Medicine, Pediatrics, Public Health and Nursing Sciences, University of California Irvine, School of Medicine, is a consultant for AstraZeneca.
• Muthiah Vaduganathan, MD, MPH, Attending Cardiologist, Brigham and Women’s Hospital, Co-Director, Cardiometabolic Center of Implementation Science, Instructor of Medicine, Harvard Medical School, has received grant/research support from, and is a consultant for, Amgen, American Regent, AstraZeneca, Baxter Healthcare, Boehringer Ingelheim / Eli Lilly, Bayer AG, Cytokinetics, Lexicon Pharmaceuticals, and Relypsa. He has served as a promotional activities’ speaker for Novartis and Roche Diagnostics.

Planning Committee
• Carole Drexel, PhD, Medical Director, PlatformQ Health Education, has no relevant financial relationships with regard to this activity.
• Jaimee Harris-Gold, Program Manager, PlatformQ Health Education, has no relevant financial relationships with regard to this activity.

Joslin CME Advisory Committee
• Jerry Cavallerano, OD, Optometrist, Beetham Eye Institute, Joslin Diabetes Center, has no relevant financial relationships.
• Nuha El Sayed, MD, Staff Physician and Medical Director, Professional Education, Joslin Diabetes Center, has no relevant financial relationships.
• Erin Kelly, M.Ed., RN, BSN, CDE, Adult Diabetes Educator, Joslin Diabetes Center, holds stock in Tandem Diabetes Care.
• Lyle Mitzner, MD, Staff Physician, Joslin Diabetes Center, is a consultant for Conversa Health.
• Alissa Segal, Pharm D, CDE, CDTC, FCCP, Clinical Pharmacist, Joslin Diabetes Center, has no relevant financial relationships.
• Robert C. Stanton, MD, Chief of Nephrology, Joslin Diabetes Center, has no relevant financial relationships
• Elena Toschi, MD, Staff Physician, Joslin Diabetes Center, has no relevant financial relationships.

* Also on the Planning Committee
† Also on the CME Advisory Committee

CONTACT INFORMATION

Please send content inquiries to: cme@joslin.harvard.edu

For technical problems with the site or issues with your CME Certificate, please contact CardioCareLive at 877-394-1306 or at Support@CardioCareLive.com or DiabetesSeriesLive at 877-394-1306 or at Support@DiabetesSeriesLive.com.

DISCLAIMERS (if applicable):

The material is prepared based on a review of multiple sources of information but is not exhaustive of the subject matter. Therefore, health care professionals and other individuals should review and consider other publications and materials about the subject matter other than relying solely on the information contained in this material.

The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by Joslin Diabetes Center, CardioCareLive, DiabetesSeriesLive, PlatformQ Health Education, LLC or the program grantor. Reasonable efforts have been made to present educational subject matter in a balanced, unbiased fashion and in compliance with regulatory requirements. Each participant must use his/her personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.